The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma
Up to 20–40% of patients with Hodgkin’s lymphoma will eventually relapse after treatment, among which early relapse confers a poor outcome. With salvage chemotherapy followed by autologous stem cell transplantation (ASCT), the long-term remission rate is 30%. We report our experience of using a modi...
Saved in:
Main Authors: | Eko A. Pangarsa, Ridho M. Naibaho, Vina Yunarvika, Budi Setiawan, Damai Santosa, Catharina Suharti |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | Case Reports in Hematology |
Online Access: | http://dx.doi.org/10.1155/2021/9632427 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma
by: Zeina Al-Mansour, et al.
Published: (2014-01-01) -
Melphalan Culprit or Confounder in Acute Encephalopathy during Autologous Hematopoietic Stem Cell Transplantation?
by: Diógenes Alayón-Laguer, et al.
Published: (2012-01-01) -
Tool Capability in Visual EAM Analytics
by: Dierk Jugel, et al.
Published: (2015-04-01) -
Evaluation of outcome and safety profile in high-dose BEAM and Benda-EAM chemotherapy with subsequent autologous stem cell transplantation in lymphoma patients
by: Kinga Krawiec, et al.
Published: (2024-07-01) -
Intravitreal Melphalan for Vitreous Seeds: Initial Experience in China
by: Xunda Ji, et al.
Published: (2016-01-01)